REGISTRATION FORMCOURSE FEES1048713 Physician - $ 235

1048713 Other Healthcare Professional - $ 135

Suffix Mr Mrs Ms Miss Dr

Name ____________________________________

Degree(s) ________________________________

Specialty _________________________________

Address __________________________________

City State Zip ______________________________

Phone ____________________________________

Fax ______________________________________

E-mail ____________________________________ A valid email address is required Failure to provide a valid email address will delay the processing of your registration and the awarding of CME credits

FORM OF PAYMENT1048713 Check (enclosed)Made payable to The Ohio State University1048713 Credit CardVisa MasterCard Discover amp American Express accepted

Credit Card ___________________________

Expiration Date ____________

Billing Address _____________________________1048713 Check if same as above

Course Cancellation Policy Requests for cancellation submitted on or before 5 pm EST February 9 2018 will receive a full refund minus a $25 processing fee No refunds can be issued after this date The Ohio State University reserves the right to cancel this program at any time and will assume no financial obligation to the registrants however registration fees will be refunded in full

FORM FOR ENDOCRINE

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Endocrine Update 2018Saturday February 24 2018Fawcett Center2400 Olentangy River RoadColumbus Ohio 43210

Sponsored by The Ohio State Universityrsquos Wexner Medical Center in cooperation with the Department of Internal Medicine Division of Endocrinology Diabetes and Metabolism

AGENDA730-800am Registration800 Welcome Kwame Osei MD800-815 Internet ndashbased QA (Pretest)

Insulin Therapies815 -845 Insulin Pump Progress in Closing the Loop - Dungan845-915 New Basal Insulins Beyond U 100 - Joseph

Diabetic Medications and Cardiovascular Disease 915-945 GLP-1 agonists and CVD outcomes- Bradley945-1005 SGLT2 Inhibitors and CVD outcomes ndashHsueh

1005-1015 BREAK

Metabolic Bone Disorders1015-1045 Update on Osteoporosis Management - Ryan1045-1105 PTH Analogs in Bone Disorders -Ing

Thyroid Disorders1105-1150 A practical approach to guideline ndashbased thyroid nodules and cancer management - Ringel1150 -1215 Panel Internet QA Posttest

The Endocrine Update was created over 20 years ago with a singular mission to educate clinical providers who treat patients with endocrine disorders The conference covers epidemiology pathophysiology diagnosis and treatment of common endocrine disorders

1215-1245 Lunch

1245-115 Meet the Professor (Small Groups) 1 Glucose monitoring - Snyder 2 Endocrine Diseases in Transplant - Meng 3 Diabetes and Pregnancy - Buschur 4 New Phases of DKA - Patel

115- 130 Internet ndashbased QA Pretest

HPA Axis130-155 Endocrine Hypertension - Kirschner155-225 Immunomodulatiing Therapy- induced Endocrine Side Effects Hypophysitis and Thyroiditis - Ghalib225-255 Transgender Endocrinology- Keaster

255 ndash 305 BREAK

ObesityLipids305-335 Pharmacological Management of Obesity- OrsquoDonnell335- 405 Novel Antilipid Agents Beyond Statins- Wyne405 -435 PanelQA Posttest

435 Closing Comments Evaluations

445 Adjourn

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

ACCREDTATION STATEMENTThe Ohio State University Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME reg) to provide continuing medical education for physicians

AMA CREDIT DESIGNATION STATEMENTThe Ohio State University Center for Continuing Medical Education designates this live activity for a maximum of 825 AMA PRA Category 1 Credit(s)TM Physicians should only claim credit commensurate with the extent of their participation in the activity

LEARNING OBJECTIVESAt the end of this activity learners will be able to

1 Evaluate the role of new novel insulins in the treatment of diabetes2 Employ the use of new technologies in diabetes care3 Identify novel drugs in the management of obesity and lipids and lipoproteins4 Describe the pathophysiology and treatment of bone disorders5 Recognize the endocrine adverse effects of cancer immunotherapy6 Select new antidiabetic medications on CVD outcomes7 Recognize the regulation of the HPA axis8 Evaluate thyroid nodule

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Endocrine Update 2018Saturday February 24 2018Fawcett Center2400 Olentangy River RoadColumbus Ohio 43210

Sponsored by The Ohio State Universityrsquos Wexner Medical Center in cooperation with the Department of Internal Medicine Division of Endocrinology Diabetes and Metabolism

AGENDA730-800am Registration800 Welcome Kwame Osei MD800-815 Internet ndashbased QA (Pretest)

Insulin Therapies815 -845 Insulin Pump Progress in Closing the Loop - Dungan845-915 New Basal Insulins Beyond U 100 - Joseph

Diabetic Medications and Cardiovascular Disease 915-945 GLP-1 agonists and CVD outcomes- Bradley945-1005 SGLT2 Inhibitors and CVD outcomes ndashHsueh

1005-1015 BREAK

Metabolic Bone Disorders1015-1045 Update on Osteoporosis Management - Ryan1045-1105 PTH Analogs in Bone Disorders -Ing

Thyroid Disorders1105-1150 A practical approach to guideline ndashbased thyroid nodules and cancer management - Ringel1150 -1215 Panel Internet QA Posttest

The Endocrine Update was created over 20 years ago with a singular mission to educate clinical providers who treat patients with endocrine disorders The conference covers epidemiology pathophysiology diagnosis and treatment of common endocrine disorders

1215-1245 Lunch

1245-115 Meet the Professor (Small Groups) 1 Glucose monitoring - Snyder 2 Endocrine Diseases in Transplant - Meng 3 Diabetes and Pregnancy - Buschur 4 New Phases of DKA - Patel

115- 130 Internet ndashbased QA Pretest

HPA Axis130-155 Endocrine Hypertension - Kirschner155-225 Immunomodulatiing Therapy- induced Endocrine Side Effects Hypophysitis and Thyroiditis - Ghalib225-255 Transgender Endocrinology- Keaster

255 ndash 305 BREAK

ObesityLipids305-335 Pharmacological Management of Obesity- OrsquoDonnell335- 405 Novel Antilipid Agents Beyond Statins- Wyne405 -435 PanelQA Posttest

435 Closing Comments Evaluations

445 Adjourn

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

ACCREDTATION STATEMENTThe Ohio State University Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME reg) to provide continuing medical education for physicians

AMA CREDIT DESIGNATION STATEMENTThe Ohio State University Center for Continuing Medical Education designates this live activity for a maximum of 825 AMA PRA Category 1 Credit(s)TM Physicians should only claim credit commensurate with the extent of their participation in the activity

LEARNING OBJECTIVESAt the end of this activity learners will be able to

1 Evaluate the role of new novel insulins in the treatment of diabetes2 Employ the use of new technologies in diabetes care3 Identify novel drugs in the management of obesity and lipids and lipoproteins4 Describe the pathophysiology and treatment of bone disorders5 Recognize the endocrine adverse effects of cancer immunotherapy6 Select new antidiabetic medications on CVD outcomes7 Recognize the regulation of the HPA axis8 Evaluate thyroid nodule